Form 4: Edgewise Therapeutics Executive Exercises Options and Sells Shares
SEC Form 4
Marc Semigran, Chief Development Officer of Edgewise Therapeutics, exercised stock options and sold shares on December 24, 2024, according to a Form 4 filing.
Summary
- On December 24, 2024, Marc Semigran, the Chief Development Officer of Edgewise Therapeutics, exercised stock options to acquire 29,709 shares of common stock at a price of $8.94 per share.
- Simultaneously, Semigran sold 27,980 shares at an average price of $29.6607 and 1,729 shares at an average price of $30.0803.
- These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 24, 2024.
- Following these transactions, Semigran directly owns 6,716 shares of common stock and holds options for 270,291 shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.
Future Outlook
NA
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives, which can be of interest to investors.
Comparison to Industry Standards
- Insider trading activity is common in publicly traded companies, and the disclosed transactions are typical for executives holding stock options and participating in employee stock purchase plans.
- The use of a 10b5-1 trading plan is a standard practice to avoid accusations of trading on inside information, similar to practices at companies like Amgen or Regeneron.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased trading volume.
- The sales could be perceived as a lack of confidence by the executive, although the use of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2022-12-20 | Date of Power of Attorney execution. |
| 2023-11-15 | Purchase of 2,187 shares under the Employee Stock Purchase Plan. |
| 2023-12-19 | 1/4th of stock options vested and exercisable. |
| 2024-05-15 | Purchase of 2,254 shares under the Employee Stock Purchase Plan. |
| 2024-09-24 | Adoption date of Rule 10b5-1 trading plan. |
| 2024-11-15 | Purchase of 2,275 shares under the Employee Stock Purchase Plan. |
| 2024-12-24 | Date of option exercise and share sales. |
| 2032-12-30 | Expiration date of stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.